PubMed HealthSearch

Biomedical subjects

Bo Han

Publications and source records attributed to Bo Han.

2 recordsLinked to original sources

Genomic and food-safety evaluation of Staphylococcus chromogenes in Chinese dairy milk.

Non-aureus staphylococci and mammaliicocci (NASM) cause mastitis and may contaminate milk and dairy products. Milk samples (n&#xa0;=&#xa0;1916) from cows with subclinical or clinical mastitis (SCM and CM, respectively) were collected from 28 large-scale (> 500 lactating cows) Chinese dairy farms. Overall, 999 NASM isolates representing 19 species were identified by MALDI-TOF MS and cpn60 sequencing, with Staphylococcuschromogenes, Mammaliicoccus sciuri and Staphylococcus haemolyticus being most prevalent. Antimicrobial resistance (AMR) was determined with disc diffusion; non-susceptible to penicillin was most common (SCM, 30% and CM, 29%) whereas cefoxitin non-susceptible NASM accounted for 8-10% of isolates; among these, 12.5% carried mecA but none carried mecC. Galleria mellonella was used to assess virulence of 78 strains of S. chromogenes, a dominant species; subsequently, 32 strains, representing higher- and lower-virulence in the Galleria model, were selected for whole-genome sequencing and comparative genomics. S. chromogenes isolates from CM had higher virulence (p&#xa0;<&#xa0;0.05) than those from SCM. The 32 genomes comprised 20 sequence types, indicating high genetic diversity. No robust genomic marker of Galleria virulence phenotype was identified in this selected WGS subset. Acquired resistance genes (n&#xa0;=&#xa0;5) were detected, including a first report of fusC in S. chromogenes; the fusC-positive isolate had an elevated fusidic acid MIC (8&#xa0;mg/L). Although S. chromogenes persisted in milk at 4&#xa0;&#xb0;C, pasteurization (64&#xa0;&#xb0;C for 30&#xa0;min) reduced viable counts to below detection. This study provided new insights into the prevalence, AMR, genomic diversity, and dairy-chain relevance of milk-derived NASM, particularly S. chromogenes. However, the genomic findings were based on an intentionally selected WGS subset and should be interpreted as hypothesis-generating rather than population-representative.

Animals

Serum N-glycomics for non-invasive detection of significant liver pathology across clinical phases of treatment-na&#xef;ve chronic hepatitis B.

BACKGROUND: Early identification of significant liver pathology is crucial for timely antiviral intervention in individuals with chronic hepatitis B (CHB) infection. Current non-invasive methods show limited accuracy in detecting occult liver damage, particularly in those with normal ALT. This study evaluated serum N-glycan profiles for diagnosing significant liver pathology in treatment-na&#xef;ve CHB patients across clinical phases. METHODS: This cross-sectional study analyzed 626 treatment-na&#xef;ve CHB patients confirmed by liver biopsy, classified according to 2025 EASL guidelines. Serum N-glycan profiles were determined using DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis. Significant liver pathology was defined as inflammation grade&#x2009;&#x2265;&#x2009;G2 and/or fibrosis stage&#x2009;&#x2265;&#x2009;S2 (per Scheuer scoring system). Multivariate logistic regression models were developed and compared with traditional non-invasive markers. RESULTS: Among 626 CHB patients, 66.0% had significant inflammation and 58.9% had significant fibrosis. Patients with significant pathology showed characteristic alterations, with elevated P1, P3, P6, P7, P11 peaks and decreased P0, P5, P8, P10 peaks (all p&#x2009;<&#x2009;0.0001). Compared to respective infection phases, hepatitis phases showed P1 increases of 19.6% and 36% in HBeAg(+) and HBeAg(-) patients, with P11 increases of 82.4% and 73.4%, while P0 decreased by 20.3% and 27.6%, and P10 by 21.6% and 20.3%. Relative to mild pathology (G and S&#x2009;<&#x2009;2), P1 increased by 27% in significant pathology (G and/or S&#x2009;&#x2265;&#x2009;2), reaching 58.7%/48.7% in G4/S4 stages (vs. G0/S0). In ALT-normal HBeAg(+) infection phase, P1 increased by 80.2%/65.8% in G4/S4 stages (vs. G0/S0), with P2 also increasing by 54.1%/45.2%. Multivariate analysis identified P11 as strongest risk factor (OR&#x2009;=&#x2009;3.84, 95%CI: 1.74-8.45, p&#x2009;=&#x2009;0.0008), followed by P1 (OR&#x2009;=&#x2009;2.04, 95%CI: 1.57-2.64, p&#x2009;<&#x2009;0.0001) and P7 (OR&#x2009;=&#x2009;1.75, 95%CI: 1.31-2.34, p&#x2009;=&#x2009;0.0002), while P2 (OR&#x2009;=&#x2009;0.07, 95%CI: 0.02-0.26, p&#x2009;<&#x2009;0.0001) and P0 (OR&#x2009;=&#x2009;0.30, 95%CI: 0.12-0.79, p&#x2009;=&#x2009;0.0140) served as protective factors. The glycomics combined model (AUC&#x2009;=&#x2009;0.876 (0.844-0.908)) achieved superior performance and outperformed the clinical model (AUC&#x2009;=&#x2009;0.818 (0.779-0.857)), LSM (AUC&#x2009;=&#x2009;0.817 (0.775-0.858)), APRI (AUC&#x2009;=&#x2009;0.830 (0.792-0.867)), and FIB-4 (AUC&#x2009;=&#x2009;0.672 (0.621-0.723)) (all p&#x2009;<&#x2009;0.001), with 78.7% sensitivity and 83.2% specificity. The optimized model reached AUC&#x2009;=&#x2009;0.917 (0.891-0.942) with accuracy 84.2%, with 78.7% sensitivity and 94.6% specificity. Both glycomics-based models maintained diagnostic capability in ALT-normal patients particularly in HBeAg(+) infection. CONCLUSIONS: Serum N-glycomics demonstrates promising potential for non-invasive identification of significant liver pathology in treatment-na&#xef;ve CHB patients, providing an alternative approach for early treatment decisions, especially in ALT-normal patients with occult liver damage.

Humans